Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

A MultGen 2 Radiofrequency Generator gains FDA clearance to provide greater efficacy in ablation procedures to give patients greater pain relief for 1 year.
The FDA is expanding the Risk Evaluation and Mitigation Strategies program to include IR opioid formulations (which already includes ER and LA opioids), and the training program will be expanded to all health professionals involved in patient pain management.
While most patients received an opioid prescription to manage post-surgical pain, fewer than 10% of patients filled and used the full prescription.
Findings from a new study on patients with back pain demonstrated that yoga and physical therapy yielded similar improvements in pain relief and improved functionality.
The first new treatment for sickle cell disease has been approved by the FDA, L-glutamine (Endari).
A new study reports that 50% of opioid prescriptions are being written for patients with co-morbid mental illness. Mental health experts believe CBT and other therapies may be preferred in this population.
Highlights of drug development news in pain management. Cara CR845, Sorrento's RTX TRPV1 agonist, and Daiichi Sankyo's microgabalin for PHN
Pain specialists don't always agree on the best use of opioids for pain management. A recent issue of JAMA presented two opposing views.
Pilot study holds promise for a new electrical stimulation device, Nerivio Migra device Theranica, Ltd, worn on the arm that is aimed at managing migraine pain.
University of Southern California is launching 2 online programs in pain management to close the knowledge gap.
The Federation of State Medical Boards has released an updated guidelines for safe opioid prescribing. This follows on the heels of a growing concern over over-prescribing of opioids, and misuse, abuse, and diversion.
In one of the first studies to consider opioid use in hospitalized elderly patients, most will respond well to alternative methods of pain relief when it is offered.
Researchers have identified DNA-PK as the enzyme responsible for mid-life weight gain and loss of exercise capacity. They also found that inhibiting DNA-PK prevented weight gain in mice, increased fitness levels, and reduced the incidence of obesity and pain.
Intraoperative ketamine does not seem to decrease the incidence of delirium or improve pain control after surgery. Study was small and used single dose versus IV infusion.
The FDA has expanded the approved use of Dysport for the treatment of spasticity in adults. Spasticity is often a result of traumatic brain injury, multiple sclerosis, and stroke.